LOS ANGELES–(BUSINESS WIRE)–Puma Biotechnology’s P 2 SUMMIT trial results of neratinib in HER2-Mutant, metastatic cervical cancers were published online in Gynecologic Oncology.
News Ticker
- [ October 13, 2026 ] Los Angeles Holds No. 1 Spot on Orkin’s 2026 Rattiest Cities List Los Angeles Biotech News
- [ October 13, 2026 ] Former U.S. Surgeon General Dr. Vivek Murthy to Headline End Well 2026 Summit, Taking On Loneliness at the End of Life Los Angeles Biotech News
- [ October 13, 2026 ] Immunis Named Semifinalist in National Academy of Medicine’s $1.5 Million Healthy Longevity Global Competition Grand Prize Los Angeles Biotech News
- [ October 13, 2026 ] egnite’s Call for Science Study on M-TEER Device Durability and Long-Term Patient Outcomes to be Featured at TCT 2026 Los Angeles Biotech News
- [ October 13, 2026 ] Pharmaceutical Sales Specialist, CVRM Specialty – Burbank, CA – Burbank, CA Los Angeles Biotech Jobs
Copyright © 2026 Biotech Networks, LLC
